CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|May 1, 2002
No advantage to omapatrilat over enalapril in heart failure . . .
The investigational vasopeptidase inhibitor omapatrilat is as effective as enalapril in preventing major adverse cardiac outcomes in patients with moderate to severe heart failure, but failed to show superiority, said Milton Packer, MD.
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Why consumers still can’t comparison shop for medication
2
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
3
Teledentistry is a step in closing the gap in dental care
4
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
5